These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 20947383

  • 1. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
    Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, Sun X, Tian H, Plotnikov AN, Burton P.
    J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
    [Abstract] [Full Text] [Related]

  • 2. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W.
    J Clin Pharmacol; 2007 Feb; 47(2):218-26. PubMed ID: 17244773
    [Abstract] [Full Text] [Related]

  • 3. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N, Arnaout L, Chabbouh T, Bellamy L.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [Abstract] [Full Text] [Related]

  • 4. [Summary and perspectives. Rivaroxaban].
    Albaladejo P.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [Abstract] [Full Text] [Related]

  • 5. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V, Perzborn E, Kubitza D, Misselwitz F.
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [Abstract] [Full Text] [Related]

  • 6. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
    Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB.
    J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
    [Abstract] [Full Text] [Related]

  • 7. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [Abstract] [Full Text] [Related]

  • 8. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G.
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [Abstract] [Full Text] [Related]

  • 9. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M.
    J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
    [Abstract] [Full Text] [Related]

  • 10. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators.
    N Engl J Med; 2008 Jun 26; 358(26):2776-86. PubMed ID: 18579812
    [Abstract] [Full Text] [Related]

  • 11. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
    Kubitza D, Becka M, Roth A, Mueck W.
    J Clin Pharmacol; 2013 Mar 26; 53(3):249-55. PubMed ID: 23381840
    [Abstract] [Full Text] [Related]

  • 12. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group.
    N Engl J Med; 2008 Jun 26; 358(26):2765-75. PubMed ID: 18579811
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V.
    Arterioscler Thromb Vasc Biol; 2010 Mar 26; 30(3):376-81. PubMed ID: 20139357
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.
    Thromb Haemost; 2008 Sep 26; 100(3):453-61. PubMed ID: 18766262
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.